Drug Profile
Research programme: photodynamic therapy - Novartis Ophthalmics/Destiny Pharma
Alternative Names: Photodynamic therapy research programme: Novartis Ophthalmics/Destiny PharmaLatest Information Update: 26 Apr 2007
Price :
$50
*
At a glance
- Originator Destiny Pharma; Novartis Ophthalmics
- Developer Destiny Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Eye disorders
Most Recent Events
- 26 Apr 2007 Discontinued - Preclinical for Eye disorders in United Kingdom (unspecified route)
- 23 Jan 2001 CIBA Vision is now called Novartis Ophthalmics
- 09 Dec 1999 Preclinical development for Eye disorders in United Kingdom (Unknown route)